70 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
, including the expected recruitment for such trials. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
or at all, the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, estimated patient … leukemia (rrCLL) and Richter transformation (RT) (cut-off date: 6 September 2023) Patient recruitment of the Phase 1 dose-finding part of EUPLAGIA-1
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Base salary Fixed pay reflects the role, skills, experience and contribution to the Company and is set at levels that support the recruitment
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
) in relapsed/refractory chronic lymphocytic leukemia (rrCLL) and Richter transformation (RT) (cut-off date: 6 September 2023)Patient recruitment of the Phase 1 … (rrNHL) (cut-off date: 1 September 2023)To further build a robust data package, patient recruitment of the Phase 1 dose-finding part of ATALANTA-1
6-K
EX-99.1
erz7p5h fgoz
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
l3nh z5qi4ts85ju
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
w6ym7l5 t7p
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
1c6wk8
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
pdu hxnonthwgwjum
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
kuqbl453pbx9vyg98cpw
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
d6vfbfammetecai4
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
jrojqs155he bdrx5t
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
s4syfqqzej1jasp8
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
dpzucjxk45wevut0 7ul
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
760nirrv 3qh
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
hp34vgpm0nmyfct8u
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
6-K
EX-99.1
w4h505z0m65swmkudkf
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
9cfe 9spf
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
6nwvpk0h68i4foneevy
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am